News Column

Data on Ovarian Cancer Reported by Researchers at University of Alabama (Inhibition of Wnt/beta-catenin pathway by niclosamide: A therapeutic target...

August 6, 2014



Data on Ovarian Cancer Reported by Researchers at University of Alabama (Inhibition of Wnt/beta-catenin pathway by niclosamide: A therapeutic target for ovarian cancer)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Oncology have been published. According to news reporting originating from Birmingham, Alabama, by NewsRx correspondents, research stated, "The Wnt/beta-catenin pathway is known to regulate cellular proliferation and plays a role in chemoresistance. Niclosamide, an FDA approved salicyclamide derivative used for the treatment of tapeworm infections, targets the Wnt/beta-catenin pathway."

Our news editors obtained a quote from the research from the University of Alabama, "Therefore, the objective of this study was to investigate niclosamide as a potential therapeutic agent for ovarian cancer. Tumor cells isolated from 34 patients' ascites with primary ovarian cancer were treated with niclosamide (0.1 to 5 mu M) +/- carboplatin (5 to 150 mu M). Cell viability was assessed using the ATP-lite assay. LRP6, Axin 2, Cyclin D1, survivin and cytosolic free p-catenin levels were determined using Western blot analysis. Tumorspheres were treated, and Wnt transcriptional activity was measured by the TOPflash reporter assay. ALDH and CD133 were analyzed by Flow cytometry and IHC. ALDH1A1 and LRP6 were analyzed by IHC in solid tumor and in ascites before and after treatment with niclosamide. Combination treatment produced increased cytotoxicity compared to single agent treatment in 32/34 patient samples. Western blot analysis showed a decrease in Wnt/beta-catenin pathway proteins and the expression of target genes. A significant reduction of Wnt/beta-catenin signaling was confirmed by TOPflash assay. There was increased staining of ALDH1A1 and LRP6 in ascites compared to solid tumor which decreased after treatment. This study demonstrates that niclosamide is a potent Wnt/beta-catenin inhibitor. Targeting the Wnt/beta-catenin pathway led to decreased cellular proliferation and increased cell death."

According to the news editors, the research concluded: "These findings warrant further research of this drug and other niclosamide analogs as a treatment option for ovarian cancer."

For more information on this research see: Inhibition of Wnt/beta-catenin pathway by niclosamide: A therapeutic target for ovarian cancer. Gynecologic Oncology, 2014;134(1):112-120. Gynecologic Oncology can be contacted at: Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA. (Elsevier - www.elsevier.com; Gynecologic Oncology - www.elsevier.com/wps/product/cws_home/622840)

The news editors report that additional information may be obtained by contacting R.C. Arend, Univ Alabama Birmingham, Dept. of Radiat Oncol, Birmingham, AL 35233, United States. Additional authors for this research include A.I. Londono-Joshi, R.S. Samant, Y.H. Li, M. Conner, B. Hidalgo, R.D. Alvarez, C.N. Landen, J.M. Straughn and D.J. Buchsbaum (see also Oncology).

Keywords for this news article include: Alabama, Ascites, Therapy, Genetics, Oncology, Birmingham, Gynecology, Niclosamide, beta Catenin, United States, Ovarian Cancer, Women's Health, Salicylanilides, Transcription Factors, North and Central America, Armadillo Domain Proteins

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters